Diabetic Neuropathy

• EMA withdrawal · 2021-06-22
  EMA Withdrawn: Nodetrip (previously Xeristar) (duloxetine) — Esteve Pharmaceuticals, S.A.

  The EMA has withdrawn Nodetrip (duloxetine) from Esteve Pharmaceuticals, covering indications in anxiety disorders, major depressive disorde…

• EMA withdrawal · 2018-08-07
  EMA Withdrawn: Ariclaim (duloxetine) — Eli Lilly Nederland B.V.

  EMA withdrew Ariclaim (duloxetine) from the market in the Diabetic Neuropathies therapeutic area.

• CLINICAL_TRIALS withdrawal · 2016-08-10
  Clinical Trial Update: Effects of Pulsatile Intravenous Insulin Delivery on Diabetic Neuropathy in pATIENTS (Pts) With Type 1 and Type 2 Diabetes [Phase 2, Phase 3]

  A Phase 2/3 clinical trial evaluating pulsatile intravenous insulin delivery for diabetic neuropathy in patients with type 1 and type 2 diab…

• CLINICAL_TRIALS withdrawal · 2016-07-27
  Clinical Trial Update: Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP) [Phase 2]

  A Phase 2 trial evaluating DS-1971a for diabetic peripheral neuropathic pain has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2016-04-15
  Clinical Trial Update: The Peripheral Mobilized Mononuclear Cell-based Therapy in Patient With Diabetic Neuropathy [NA]

  A clinical trial of a peripheral mobilized mononuclear cell–based therapy for diabetic neuropathy has been withdrawn.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS withdrawal · 2015-08-26
  Clinical Trial Update: Clinical Trial Designed to Determine the Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy [Phase 2]

  The Phase 2 trial of EMA401 for painful diabetic neuropathy has been withdrawn.

• EMA withdrawal · 2008-09-26
  EMA Application withdrawn: Lacosamide Pain UCB Pharma (lacosamide) — UCB Pharma S.A.

  EC withdrawal of lacosamide pain application from UCB Pharma for diabetic neuropathies.